A Phase I Study of LY3410738 in Patients with Advanced Blood Cancers with IDH1 or IDH2 Mutations


Full Title

A Phase I Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations


The purpose of this study is to find the highest dose of the investigational drug LY3410738 that can be given safely in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or continued to grow despite treatment and contains mutations in the IDH1 or IDH2 genes. LY3410738 works by blocking the mutated IDH1 and IDH2 proteins that are believed to play an active role in the growth of cancer. LY3410738 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced recurrent or persistent AML or MDS that contains mutated IDH1 or IDH2.
  • At least 2 weeks must pass since the completion of prior treatment and receipt of LY3410738.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Eytan Stein at 646-608-3749.